U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H23NO3.C10H16O4S
Molecular Weight 545.687
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHYLMORPHINE CAMSILATE

SMILES

CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.[H][C@@]34OC5=C(OCC)C=CC6=C5[C@@]37CCN(C)[C@H](C6)[C@]7([H])C=C[C@@H]4O

InChI

InChIKey=NKOFCJOTATYGHA-LAZTUONISA-N
InChI=1S/C19H23NO3.C10H16O4S/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h4-7,12-14,18,21H,3,8-10H2,1-2H3;7H,3-6H2,1-2H3,(H,12,13,14)/t12-,13+,14-,18-,19-;7-,10-/m01/s1

HIDE SMILES / InChI

Molecular Formula C10H16O4S
Molecular Weight 232.297
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C19H23NO3
Molecular Weight 313.3908
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Ethylmorphine is a derivative of morphine with analgesic and antitussive effect. It acts by activating the opioid receptors and thus has a direct influence on the CNS system. Ethylmorphine was approved in Europe for the treatment of dry cough (Codethyline, Dionine).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
345.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CODETHYLINE

Approved Use

A cough medicine.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.09 μM
1.5 mg/kg bw single, oral
dose: 1.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHYLMORPHINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
222 μM × min
1.5 mg/kg bw single, oral
dose: 1.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHYLMORPHINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.97 h
1.5 mg/kg bw single, oral
dose: 1.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHYLMORPHINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
8.5 mg single, oral
Dose: 8.5 mg
Route: oral
Route: single
Dose: 8.5 mg
Sources:
healthy, 10 months
n = 1
Health Status: healthy
Age Group: 10 months
Sex: M
Population Size: 1
Sources:
Other AEs: Sedation...
Other AEs:
Sedation (grade 5)
Sources:
1.5 mg/kg single, oral
Dose: 1.5 mg/kg
Route: oral
Route: single
Dose: 1.5 mg/kg
Sources:
healthy, 24 years
n = 10
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 10
Sources:
Other AEs: Dizziness, Drowsiness...
Other AEs:
Dizziness (7 patients)
Drowsiness (slight, 2 patients)
Loose stools (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Sedation grade 5
8.5 mg single, oral
Dose: 8.5 mg
Route: oral
Route: single
Dose: 8.5 mg
Sources:
healthy, 10 months
n = 1
Health Status: healthy
Age Group: 10 months
Sex: M
Population Size: 1
Sources:
Loose stools 1 patient
1.5 mg/kg single, oral
Dose: 1.5 mg/kg
Route: oral
Route: single
Dose: 1.5 mg/kg
Sources:
healthy, 24 years
n = 10
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 10
Sources:
Dizziness 7 patients
1.5 mg/kg single, oral
Dose: 1.5 mg/kg
Route: oral
Route: single
Dose: 1.5 mg/kg
Sources:
healthy, 24 years
n = 10
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 10
Sources:
Drowsiness slight, 2 patients
1.5 mg/kg single, oral
Dose: 1.5 mg/kg
Route: oral
Route: single
Dose: 1.5 mg/kg
Sources:
healthy, 24 years
n = 10
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 10
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim
PubMed

PubMed

TitleDatePubMed
Acute renal failure due to concomitant action of methotrexate and indomethacin.
1986 Jun 14
Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose.
1995 Jun
Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model.
1997 Apr
[Experimental study on using diclofenac sodium or dionine topically to treat fibrinous membrane after intraocular lens implantation].
2001 Jun 28
Enzyme immunoassay validation for the detection of buprenorphine in urine.
2003 Mar
Interpretation of the presence of 6-monoacetylmorphine in the absence of morphine-3-glucuronide in urine samples: evidence of heroin abuse.
2003 Oct
Genomic characterization and regulation of CYP3a13: role of xenobiotics and nuclear receptors.
2003 Sep
Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens.
2004 Jul 16
Biochemical background of toxic interaction between tiamulin and monensin.
2004 Mar 15
Screening for drugs of abuse in hair with ion spray LC-MS-MS.
2004 Oct 29
[Current problems in the quality control of pharmaceutical preparations manufactured in pharmacies II. Paracetamol contraining preparations].
2006
A hybrid FIA/HPLC system incorporating monolithic column chromatography.
2007 Sep 26
[Study of cytotoxic and antiviral effects of some eye drops].
2008
Error in the article: "driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood".
2008 Jun
Driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood.
2008 May
Determination of opiates and cocaine in urine by high pH mobile phase reversed phase UPLC-MS/MS.
2009 Feb 1
[Pharmacological treatment of acute cough].
2009 May 14
[The effect of warfarin was potentiated by an antitussive. Cocillana-Etyfin increased the PK(INR) value].
2009 Nov 4-12
Characterization of xenobiotic metabolizing enzymes in bovine small intestinal mucosa.
2010 Jun 1
Effect of cytisine on some brain and hepatic biochemical parameters in spontaneously hypertensive rats.
2010 Mar
Death of a 10-month-old boy after exposure to ethylmorphine.
2010 Mar 1
Patents

Sample Use Guides

The recommended dose in adults is 50 mg of codethyline per day, i.e. 10 tablets (1 tablet contains 5 mg of ethylmorphine hydrochloride) per day over several intakes, at a minimum of 4 hours apart. In children the normal dose is 1 tablet per intake, to be renewed after 6 hours if necessary, without exceeding 4 tablets per day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:07:06 GMT 2023
Edited
by admin
on Sat Dec 16 11:07:06 GMT 2023
Record UNII
RX4SJ3L382
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHYLMORPHINE CAMSILATE
Common Name English
ETHYLMORPHINE CAMPHOSULFONATE
Common Name English
MORPHINAN-6-OL, 7,8-DIDEHYDRO-4,5-EPOXY-3-ETHOXY-17-METHYL-, (5.ALPHA.,6.ALPHA.)-, (1S)-7,7-DIMETHYL-2-OXOBICYCLO(2.2.1)HEPTANE-1-METHANESULFONATE
Systematic Name English
Ethylmorphine camsilate [WHO-DD]
Common Name English
Code System Code Type Description
FDA UNII
RX4SJ3L382
Created by admin on Sat Dec 16 11:07:06 GMT 2023 , Edited by admin on Sat Dec 16 11:07:06 GMT 2023
PRIMARY
ECHA (EC/EINECS)
279-118-1
Created by admin on Sat Dec 16 11:07:06 GMT 2023 , Edited by admin on Sat Dec 16 11:07:06 GMT 2023
PRIMARY
PUBCHEM
91808966
Created by admin on Sat Dec 16 11:07:06 GMT 2023 , Edited by admin on Sat Dec 16 11:07:06 GMT 2023
PRIMARY
SMS_ID
100000088240
Created by admin on Sat Dec 16 11:07:06 GMT 2023 , Edited by admin on Sat Dec 16 11:07:06 GMT 2023
PRIMARY
CAS
79241-89-7
Created by admin on Sat Dec 16 11:07:06 GMT 2023 , Edited by admin on Sat Dec 16 11:07:06 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE